LP
TNGX icon

LMR Partners’s Tango Therapeutics TNGX Stock Holding History

LMR Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,000
Closed -$120K – 1522
2024
Q2 		$120K Hold
14,000
– – ﹤0.01% 886
2024
Q1 		$111K Hold
14,000
– – ﹤0.01% 915
2023
Q4 		$139K Sell
14,000
-11,000
-44% -$95.5K ﹤0.01% 749
2023
Q3 		$282K Hold
25,000
– – ﹤0.01% 610
2023
Q2 		$83K Hold
25,000
– – ﹤0.01% 633
2023
Q1 		$98.8K Hold
25,000
– – ﹤0.01% 939
2022
Q4 		$181K Buy
25,000
+8,325
+50% +$58.6K ﹤0.01% 1006
2022
Q3 		$60K Hold
16,675
– – ﹤0.01% 1082
2022
Q2 		$76K Sell
16,675
-8,325
-33% -$50.4K ﹤0.01% 1119
2022
Q1 		$190K Sell
25,000
-13,459
-35% -$117K ﹤0.01% 1149
2021
Q4 		$421K Buy
+38,459
New +$463K ﹤0.01% 947

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LMR Partners's TNGX Position: Q3 2024 in Review

LMR Partners sold out of Tango Therapeutics (TNGX) in Q3 2024, closing a stake of 14,000 shares — an estimated $120K sold.

LMR Partners first reported a position in TNGX in Q4 2021 and held it in 11 quarters. The position peaked at $421K in Q4 2021. 121 funds tracked by Wall St. Rank hold TNGX as of Q3 2024.

  • LMR Partners reported no remaining Tango Therapeutics position as of Q3 2024 after selling out during the quarter.
  • LMR Partners sold 14,000 Tango Therapeutics shares in Q3 2024, an estimated $120K.
  • LMR Partners first reported a position in Tango Therapeutics in Q4 2021 and held it in 11 quarters.
  • LMR Partners's Tango Therapeutics position peaked at $421K in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.